Menthol
(NOOLISFMXDJSKH-UHFFFAOYSA-N)
Structure
- SMILES
- CC1CCC(C(C1)O)C(C)C
- Molecular Formula:
- C10H20O
- Molecular Weight:
- 156.265
- Log P:
- 2.4395
- Hydrogen Bond Acceptor:
- 1
- Hydrogen Bond Donor:
- 1
- TPSA:
- 20.23
- CAS Number(s):
- 89-78-1; 1490-04-6; 3623-51-6; 15356-70-4
Synonym(s)
1.
Menthol
2.
Menthol, (1alpha,2beta,5alpha)-Isomer
External Link(s)
Adverse Drug Event(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Chemical injury | FAERS: 12 | US FAERS | |
| 2 | Erythema | FAERS: 11 | US FAERS | |
| 3 | Application site burn | FAERS: 9 | US FAERS | |
| 4 | Thermal burn | FAERS: 9 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 5 | Application site pain | FAERS: 7 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 6 | Application site vesicles | FAERS: 6 | US FAERS | |
| 7 | Pain | FAERS: 6 | CTD US FAERS | |
| 8 | Application site erythema | FAERS: 3 | US FAERS | |
| 9 | Burning sensation | FAERS: 3 | US FAERS | |
| 10 | Chemical burn of skin | FAERS: 3 | US FAERS | |
| 11 | Product quality issue | FAERS: 3 | US FAERS | |
| 12 | Application site discomfort | FAERS: 2 | US FAERS | |
| 13 | Application site pruritus | FAERS: 2 | US FAERS | |
| 14 | Application site scar | FAERS: 2 | US FAERS | |
| 15 | Feeling abnormal | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 16 | Nerve injury | FAERS: 2 | US FAERS | |
| 17 | Skin irritation | FAERS: 2 | US FAERS | |
| 18 | Abasia | FAERS: 1 | US FAERS | |
| 19 | Alanine Aminotransferase Increased | FAERS: 1 | US FAERS | |
| 20 | Allodynia | FAERS: 1 | US FAERS | |
| 21 | Aphthous Stomatitis | FAERS: 1 | US FAERS | |
| 22 | Application site inflammation | FAERS: 1 | US FAERS | |
| 23 | Application site scab | FAERS: 1 | US FAERS | |
| 24 | Application site swelling | FAERS: 1 | US FAERS | |
| 25 | Application site warmth | FAERS: 1 | US FAERS | |
| 26 | Aspartate Aminotransferase Increased | FAERS: 1 | US FAERS | |
| 27 | Asthenia | FAERS: 1 | US FAERS | |
| 28 | Ataxia | FAERS: 1 | US FAERS | |
| 29 | Back disorder | FAERS: 1 | US FAERS | |
| 30 | Blood bilirubin unconjugated increased | FAERS: 1 | US FAERS | |
| 31 | Blood creatine phosphokinase increased | FAERS: 1 | US FAERS | |
| 32 | Blood potassium increased | FAERS: 1 | US FAERS | |
| 33 | Chromaturia | FAERS: 1 | US FAERS | |
| 34 | Deformity | FAERS: 1 | US FAERS | |
| 35 | Discomfort | FAERS: 1 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 36 | Disorientation | FAERS: 1 | US FAERS | |
| 37 | Dizziness | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 38 | Drug ineffective | FAERS: 1 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 39 | Dyspepsia | FAERS: 1 | US FAERS | |
| 40 | Excoriation | FAERS: 1 | US FAERS | |
| 41 | Impaired work ability | FAERS: 1 | US FAERS | |
| 42 | Inflammation | FAERS: 1 | US FAERS | |
| 43 | Liquid product physical issue | FAERS: 1 | US FAERS | |
| 44 | Macule | FAERS: 1 | US FAERS | |
| 45 | Middle insomnia | FAERS: 1 | US FAERS | |
| 46 | Myalgia | FAERS: 1 | US FAERS | |
| 47 | Oliguria | FAERS: 1 | US FAERS | |
| 48 | Open wound | FAERS: 1 | US FAERS | |
| 49 | Pain of skin | FAERS: 1 | US FAERS | |
| 50 | Product container issue | FAERS: 1 | US FAERS | |
| 51 | Renal tubular necrosis | FAERS: 1 | US FAERS | |
| 52 | Rhabdomyolysis | FAERS: 1 | US FAERS | |
| 53 | Scab | FAERS: 1 | US FAERS | |
| 54 | Secretion discharge | FAERS: 1 | US FAERS | |
| 55 | Skin Ulcer | FAERS: 1 | US FAERS | |
| 56 | Sunburn | FAERS: 1 | US FAERS | |
| 57 | Toxicity to various agents | FAERS: 1 | US FAERS | |
| 58 | Wrong technique in drug usage process | FAERS: 1 | US FAERS | |
| 59 | Accidental exposure to product | Canada Vigilance: 1 | Canada Vigilance | |
| 60 | Anxiety | Canada Vigilance: 1 | Canada Vigilance | |
| 61 | Drug Dependence | Canada Vigilance: 1 | Canada Vigilance | |
| 62 | Emotional disorder | Canada Vigilance: 1 | Canada Vigilance | |
| 63 | Eye irritation | Canada Vigilance: 2 | Canada Vigilance | |
| 64 | Fatigue | Canada Vigilance: 1 | Canada Vigilance | |
| 65 | Frustration tolerance decreased | Canada Vigilance: 1 | Canada Vigilance | |
| 66 | Headache | Canada Vigilance: 1 | Canada Vigilance | |
| 67 | Hyperalgesia | 15931068 16527405 18440147 | CTD | |
| 68 | Liver Cirrhosis | 14731143 | CTD | |
| 69 | Motor Skills Disorders | 20538177 | CTD | |
| 70 | Nausea | Canada Vigilance: 1 | Canada Vigilance | |
| 71 | Necrosis | 3556044 16433031 | CTD | |
| 72 | Nephritis, Interstitial | 3556044 | CTD | |
| 73 | Nervousness | Canada Vigilance: 1 | Canada Vigilance | |
| 74 | Neuralgia | 16920620 | CTD | |
| 75 | Occupational Diseases | 5686414 | CTD | |
| 76 | Olfaction Disorders | 5686414 | CTD | |
| 77 | Quality of life decreased | Canada Vigilance: 1 | Canada Vigilance | |
| 78 | Sensation Disorders | 21550252 | CTD | |
| 79 | Skin necrosis | Canada Vigilance: 1 | Canada Vigilance | |
| 80 | Vomiting | Canada Vigilance: 1 | Canada Vigilance |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120234
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.